Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463771 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
A Phase 2 study of Endometrial Cancer, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04463771 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 206 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04463771, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Conditions Studied
Interventions
- DRUG INCAGN02385
- DRUG INCAGN02390
- DRUG retifanlimab
- DRUG epacadostat
- DRUG pemigatinib
Study Locations (20)
Florida
- Broward Health Medical Center - Fort Lauderdale
- Miami Cancer Institute - Miami
- Mount Sinai Medical Center Comprehensive Cancer Center - Miami Beach
- Advent Health Medical Group-Orlando 2501 - Orlando
- H. Lee Moffitt Cancer Center and Research Institute Hospital - Tampa
Arizona
- Honorhealth - Phoenix
- Arizona Oncology Associates - Tucson
California
- UCLA Medical Hematology & Oncology - Los Angeles
- Olive View Med Ctr - Sylmar
Missouri
- Midwest Cancer Care - Kansas City
- Washington University - St Louis
Alaska
- Alaska Womens Cancer Care Akwcc - Anchorage
Georgia
- Georgia Cancer Center - Augusta
Michigan
- Barbara Ann Karmanos Cancer Hospital - Detroit
Minnesota
- Minnesota Oncology-Maplewood - Coon Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2026-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463771
The ClinicalTrials.gov registry entry for NCT04463771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 5 interventions - of which INCAGN02385 is the first listed.
NCT04463771 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04463771 about?
NCT04463771 is a clinical study titled "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.". This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immun...
What is the current status of trial NCT04463771?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2021-01-26. Estimated completion is 2026-07-10.
What conditions does trial NCT04463771 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04463771?
The interventions under investigation include: INCAGN02385 (DRUG), INCAGN02390 (DRUG), retifanlimab (DRUG), epacadostat (DRUG), pemigatinib (DRUG).
Who is sponsoring clinical trial NCT04463771?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04463771 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.